Loading…
Loading…
Announcements from Anixa Biosciences, published the moment they cross the wire. Get them by email.
2019
Feb 28, 2019
7:00 AM EST
It will present data in an oral minisymposium presentation from its study utilizing Anixa's artificial intelligence (AI) driven early cancer detection technology. The presentation will be made at the 2019 annual meeting of the American Association for Cancer Research (AACR) in Atlanta , Georgia.
Feb 25, 2019
7:00 AM EST
It has entered into a strategic alliance with ResearchDx to launch its Cchek™ Prostate Cancer Confirmation (Cchek™ PCC) test as a Laboratory Developed Test. ResearchDx is a CLIA certified, CAP Accredited laboratory located in Southern California.
Feb 21, 2019
7:00 AM EST
It has extended its collaboration with The Wistar Institute and Dmitry I. Gabrilovich , M.D., Ph.D. Gabrilovich is a pioneer in the field of myeloid-derived suppressor cell (MDSC) biology and its roles in cancer progression and therapy response.
Feb 13, 2019
7:00 AM EST
Dr. Amit Kumar , its President and CEO, will be presenting on a panel discussion at Moffitt Cancer Center's 13 th Annual Business of Biotech Conference being held on February 22, 2019 .
Jan 25, 2019
7:00 AM EST
It has made a recording of its January 24, 2019 conference call available on its website. The recording can be found on the Investor Presentation page of the company's website at www.anixa.com .
Jan 24, 2019
7:00 AM EST
The U.S. Patent and Trademark Office has issued a Notice of Allowance for the first patent covering Anixa subsidiary, Certainty Therapeutics, Inc.'s, CAR-T cancer treatment technology.
Jan 16, 2019
7:30 AM EST
It will hold a conference call on January 24, 2019 at 1:30 p.m. Pacific / 4:30 p.m. Eastern to discuss its plan for 2019, including the commercialization path and timeline for Cchek™, its artificial intelligence based cancer diagnostic test, and the clinical path of its CAR-T based ovarian cancer therapeutic program.
2018
Dec 19, 2018
7:00 AM EST
It completed a Pre-Submission (Pre-Sub) meeting with the US FDA on December 17 , 2018.
Dec 03, 2018
7:00 AM EST
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on using the body's immune system to fight cancer, presented the latest data from its ongoing study focusing on early detection of breast cancer, utilizing Cchek™, its artificial intelligence (AI) driven cancer detection technology, at the…
Nov 15, 2018
7:00 AM EST
It will present data from its ongoing studies in breast cancer utilizing Cchek™, Anixa's artificial intelligence (AI) driven early cancer detection technology, at the AACR Special Conference on Tumor Immunology and Immunotherapy.
Nov 12, 2018
7:00 AM EST
Its two presentations at the 33 rd Annual Meeting of The Society for Immunotherapy of Cancer (SITC) are now available on its website at www.anixa.com . The presentations discuss the ongoing studies utilizing Cchek™, Anixa's artificial intelligence (AI) driven early cancer detection technology.
Oct 29, 2018
7:00 AM EDT
It will present data from its ongoing studies utilizing Cchek™, Anixa's artificial intelligence (AI) driven early cancer detection technology, at the 33 rd Annual Meeting of The Society for Immunotherapy of Cancer (SITC).
Oct 24, 2018
7:00 AM EDT
A Pre-Submission (Pre-Sub) meeting with the US FDA has been scheduled on Monday, December 17 , 2018. The meeting is to discuss the proposed preclinical and clinical performance testing plan required to support a pre-market application, and to determine the appropriate regulatory pathway for the Cchek™ prostate cancer…
Oct 17, 2018
7:00 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on using the body's immune system to fight cancer, presented the results from its ongoing study utilizing Cchek™, its artificial intelligence (AI) driven early cancer detection technology, at the 30th Anniversary AACR Special Conference –…
Oct 15, 2018
7:00 AM EDT
It has filed an IVD pre-submission with the US Food and Drug Administration (FDA) for use of its Cchek ™ artificial intelligence based cancer detection technology, as a prostate cancer test.
Oct 11, 2018
7:00 AM EDT
It has added to its Scientific Advisory Board, Jose Conejo-Garcia , MD PhD; Marco Davila , MD PhD; Linda Kelley , PhD; and Daniel Abate-Daga , PhD; the lead scientists from Moffitt Cancer Center developing a novel ovarian cancer CAR-T treatment.
Oct 05, 2018
7:00 AM EDT
It will present data from its ongoing studies utilizing Cchek™, Anixa's artificial intelligence (AI) driven early cancer detection technology, at the 30 th Anniversary AACR Special Conference – Convergence: Artificial Intelligence, Big Data and Prediction in Cancer.
